Bliss GVS Pharma
155.47
-2.48(-1.57%)
Market Cap₹1,664.30 Cr
PE Ratio19.46
IndustryHealthcare
Company Performance:
1D-1.57%
1M+16.25%
6M-12.40%
1Y+50.90%
5Y+60.53%
View Company Insightsright
Latest news about Bliss GVS Pharma
Bliss GVS Pharma Reports Impressive Q4 Turnaround with 155.4 Crore Profit May 13, 2025
Bliss GVS Pharma Ltd. has achieved a significant financial turnaround in Q4, reporting a consolidated net profit of 155.4 crore rupees compared to a 91.5 crore rupees loss in the same quarter last year. Revenue remained stable at 198.00 crore rupees year-over-year. The company's sequential growth shows profit increased from 23.80 crore rupees in the previous quarter. Despite stable revenue, Bliss GVS Pharma demonstrated improved operational efficiency with decreased interest costs, indicating better debt management.
Bliss GVS Pharma Reports Mixed Q4 Results: Profit Turnaround Amid EBITDA Decline May 12, 2025
Bliss GVS Pharma's U.S. Partner Secures FDA Approval for Mesalamine Suppositories Apr 15, 2025